Immune Checkpoint Inhibitors In Renal Cell Carcinoma

Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26095 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma